What is the preferred antihypertensive regimen for an adult with chronic reduced‑ejection‑fraction heart failure and coexisting hypertension?

Antihypertensive Management in Heart Failure with Reduced Ejection Fraction

For adults with chronic HFrEF and hypertension, use guideline-directed medical therapy (GDMT) medications that simultaneously treat both conditions: ACE inhibitors or ARBs (preferably switching to sacubitril/valsartan), evidence-based beta-blockers (carvedilol, metoprolol succinate, or bisoprolol), mineralocorticoid receptor antagonists, and SGLT2 inhibitors, with a target blood pressure <130/80 mmHg. 1

First-Line Medication Classes for HFrEF with Hypertension

The 2017 ACC/AHA guidelines explicitly state that medications with compelling indications for HF should be used as first-line therapy to treat hypertension in HFrEF patients 1. These include:

1. Renin-Angiotensin System Inhibitors

• ACE inhibitors or ARBs are foundational therapy, but sacubitril/valsartan (ARNI) is superior and should replace ACE inhibitors in symptomatic patients (NYHA class II-IV) 1, 2
• Sacubitril/valsartan provides at least 20% mortality reduction compared to ACE inhibitors alone 1, 2
• Start sacubitril/valsartan at 49/51 mg twice daily, titrating to target dose of 97/103 mg twice daily 2, 3

2. Evidence-Based Beta-Blockers

• Only three beta-blockers have proven mortality benefit: carvedilol, metoprolol succinate, or bisoprolol 1, 2
• These agents reduce mortality by at least 20-34% and decrease sudden cardiac death 1, 2
• Carvedilol is specifically preferred in HFrEF patients 1
• Target doses: carvedilol 25-50 mg twice daily, metoprolol succinate 200 mg daily, or bisoprolol 10 mg daily 2

3. Mineralocorticoid Receptor Antagonists (MRAs)

• Spironolactone or eplerenone provide at least 20% mortality reduction and reduce sudden cardiac death 1, 2
• Start spironolactone 12.5-25 mg daily, titrating to 50 mg daily 2
• Requires monitoring of potassium and renal function 2, 3

4. SGLT2 Inhibitors

• Dapagliflozin 10 mg daily or empagliflozin 10 mg daily reduce cardiovascular death and HF hospitalization regardless of diabetes status 2, 3
• These have minimal blood pressure effects, making them ideal first agents in patients with borderline BP 2

5. Diuretics for Volume Management

• Loop diuretics (furosemide, torsemide, bumetanide) are essential for congestion control but do not reduce mortality 1, 2
• Thiazide diuretics (particularly chlorthalidone) have shown benefit in preventing HF in hypertensive patients 1

Blood Pressure Target

Target systolic BP <130 mmHg in HFrEF patients with hypertension 1, 4. This recommendation is based on guidance from the 2017 ACC/AHA/HFSA heart failure focused update, though clinical trials evaluating optimal BP targets specifically in HFrEF populations have not been performed 1.

Critical Medication Sequencing Strategy

Start all four foundational medication classes simultaneously as soon as possible after diagnosis 2, 3:

1. Begin with SGLT2 inhibitor and MRA first since they have minimal blood pressure effects 2
2. Then add beta-blocker if heart rate >70 bpm 2
3. Finally, initiate or uptitrate ARNI/ACE inhibitor/ARB 2
4. Titrate one drug at a time every 1-2 weeks using small increments until target or maximally tolerated dose is achieved 2

Medications to AVOID in HFrEF

Nondihydropyridine calcium channel blockers (verapamil, diltiazem) are contraindicated in HFrEF as they have myocardial depressant activity and worsen outcomes 1, 2. Several clinical trials demonstrated either no benefit or worse outcomes with these agents 1.

Alpha-blockers (doxazosin, terazosin, prazosin) should generally be avoided as they can worsen hypotension and interfere with GDMT optimization 1, 2.

Managing Low Blood Pressure During Optimization

A common pitfall is withholding or down-titrating GDMT due to asymptomatic hypotension 2. Never discontinue GDMT for asymptomatic hypotension with adequate perfusion 2. GDMT medications maintain efficacy and safety even in patients with baseline systolic BP <110 mmHg 2.

If symptomatic hypotension occurs (SBP <80 mmHg or major symptoms):

1. Address reversible non-HF causes first: stop alpha-blockers, discontinue other non-essential BP-lowering medications, evaluate for dehydration or infection 2
2. Use non-pharmacological interventions: compression leg stockings, exercise training, adequate salt/fluid intake if not volume overloaded 2
3. Only if symptoms persist: reduce GDMT in this specific order—if heart rate >70 bpm, reduce ARNI/ACE inhibitor/ARB dose first; if heart rate <60 bpm, reduce beta-blocker dose first 2
4. Always maintain SGLT2 inhibitor and MRA as they have minimal BP effects 2

Special Considerations for HFpEF

For patients with HFpEF and hypertension, the 2017 ACC/AHA guidelines recommend 1:

• Diuretics for volume overload (Class I recommendation)
• ACE inhibitors or ARBs and beta-blockers titrated to achieve SBP <130 mmHg after volume management (Class I recommendation)
• Hypertension is the most important cause of HFpEF, with prevalence of 60-89% in large trials 1

Common Pitfalls to Avoid

1. Delaying initiation of all four medication classes simultaneously 2
2. Accepting suboptimal doses due to unfounded BP concerns—clinical trials demonstrated benefits at target doses, not low doses 2
3. Stopping medications for asymptomatic hypotension—adverse events occur in 75-85% of HFrEF patients regardless of treatment, with no substantial difference between GDMT and placebo 2
4. Using non-evidence-based beta-blockers (e.g., atenolol, metoprolol tartrate)—only carvedilol, metoprolol succinate, and bisoprolol have proven mortality benefit 2
5. Combining ACE inhibitor with ARNI (risk of angioedema) or triple combination of ACE inhibitor + ARB + MRA (risk of hyperkalemia and renal dysfunction) 2

Monitoring Requirements

Monitor blood pressure, renal function, and electrolytes at 1-2 weeks after each dose increment 2. Modest increases in creatinine (up to 30% above baseline) are acceptable and should not prompt discontinuation 2. Potassium levels require close monitoring with MRAs, but consider potassium binders (e.g., patiromer) rather than discontinuing life-saving medications if hyperkalemia develops 2.